760 related articles for article (PubMed ID: 35831798)
1. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
[TBL] [Abstract][Full Text] [Related]
2. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
3. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
[TBL] [Abstract][Full Text] [Related]
5. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Sadoff J; Le Gars M; Brandenburg B; Cárdenas V; Shukarev G; Vaissiere N; Heerwegh D; Truyers C; de Groot AM; Jongeneelen M; Kaszas K; Tolboom J; Scheper G; Hendriks J; Ruiz-Guiñazú J; Struyf F; Van Hoof J; Douoguih M; Schuitemaker H
Vaccine; 2022 Jul; 40(32):4403-4411. PubMed ID: 35667914
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
[TBL] [Abstract][Full Text] [Related]
7. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
8. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
[TBL] [Abstract][Full Text] [Related]
10. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
Kitchin D; Richardson SI; van der Mescht MA; Motlou T; Mzindle N; Moyo-Gwete T; Makhado Z; Ayres F; Manamela NP; Spencer H; Lambson B; Oosthuysen B; Kaldine H; du Pisanie M; Mennen M; Skelem S; Williams N; Ntusi NAB; Burgers WA; Gray GG; Bekker LG; Boswell MT; Rossouw TM; Ueckermann V; Moore PL
Cell Rep Med; 2022 Mar; 3(3):100535. PubMed ID: 35474744
[TBL] [Abstract][Full Text] [Related]
11. The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.
Serwanga J; Kato L; Oluka GK; Ankunda V; Sembera J; Baine C; Kitabye I; Namuyanja A; Opio S; Katende JS; Ejou P; ; Kaleebu P
Front Immunol; 2024; 15():1384668. PubMed ID: 38779677
[TBL] [Abstract][Full Text] [Related]
12. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Lawpoolsri S; Nanthapisal S; Jongkaewwattana A; Duangdee C; Kamolratanakul S; Luvira V; Thanthamnu N; Chantratita N; Thitithanyanont A; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2024 May; ():. PubMed ID: 38744598
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection.
Jeewandara C; Aberathna IS; Dayarathna S; Nimasha T; Ranasinghe T; Jayamali J; Kamaladasa A; Karunanada M; Perera L; Ogg GS; Malavige GN
PLoS One; 2022; 17(10):e0274845. PubMed ID: 36227884
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
[TBL] [Abstract][Full Text] [Related]
16. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
[TBL] [Abstract][Full Text] [Related]
17. PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals.
Ramezani A; Sorouri R; Haji Maghsoudi S; Dahmardeh S; Doroud D; Sadat Larijani M; Eybpoosh S; Mostafavi E; Olyaeemanesh A; Salehi-Vaziri M; Bavand A; Zarghani G; Moradi L; Ashrafian F; Bagheri Amiri F; Mashayekhi P; Tahmasebi Z; Biglari A
Sci Rep; 2023 May; 13(1):8065. PubMed ID: 37202438
[TBL] [Abstract][Full Text] [Related]
18. Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
El-Shesheny R; El Taweel A; Gomaa MR; Roshdy WH; Kandeil A; Webby RJ; Kayali G; Ali MA
Vaccine; 2022 Jul; 40(32):4303-4306. PubMed ID: 35697574
[TBL] [Abstract][Full Text] [Related]
19. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study.
Hyun H; Choi MJ; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
J Korean Med Sci; 2022 Jul; 37(27):e210. PubMed ID: 35818701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
